Impact of Rheumatoid Factor Levels on Drug Survival of Certolizumab and Adalimumab in Rheumatoid Arthritis: A Real-World Cohort Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #455; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Certolizumab pegol demonstrated superior drug survival compared with Adalimumab in this real-world RA biologic naive cohort. This difference was particularly pronounced among patients with elevated RF levels, supporting the hypothesis that absence of the Fc fragment may reduce the negative impact of RF on biologic survival. These findings suggest that RF magnitude may be a useful factor when selecting biologic therapy in RA."
Clinical • Real-world • Real-world evidence • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Rheumatoid Arthritis • Rheumatology
|
|
Fábio Augusto da Rocha Specian1; Felipe Alexandre Uechi1; Nadia Aikawa2; Ana Luppino Assad3; Renata Miossi3; Fernando Souza4; Carlos Insfran Echauri1; Henrique Ayres Mayrink Giardini5; André Silva Franco1; Diogo Souza Domiciano6; Thiago Quadrante Freitas7; Julio de Moraes1; Eloisa Bonfa8; Carla Saad1; Karina Bonfiglioli1; Ana Medeiros-Ribeiro9; Andrea Shimabuco1
|